A Long-Term Extension Study of WA22763 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Patients who have completed the 97-week WA22762 core study on subcutaneous or intravenous RoActemra/Actemra and who experienced at any time during WA22762 clinically significant improvement in DAS28 (>1.2 points), and based on the investigator's judgment may continue to benefit from RoActemra/Actemra treatment in this study investigating the subcutaneous formulation
• No current or recent adverse events or laboratory findings preventing the use of the study drug dose of RoActemra/Actemra 162 mg sc at baseline visit
• Receiving treatment on an outpatient basis
• Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception during the study and for at least 3 months following the last dose of study drug
• Oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) up to the recommended dose are permitted if on stable dose regimen for >/= 4 weeks prior to baseline
• Permitted non-biological disease-modifying anti-rheumatic drugs (DMARDs) are allowed

Exclusion Criteria:

• Patients who have prematurely withdrawn from the WA22762 core study for any reason
• Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies
• Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL)1 agent, or a T-cell costimulation modulator since the last administration of study drug in the WA22762 core study
• Immunization with a live/attenuated vaccine since the last administration of study drug in the WA22762 core study
• Diagnosis since last WA22762 visit (Week 97) of rheumatic disease other than rheumatoid arthritis; secondary Sjörgen's syndrome with RA is permitted
• Diagnosis since last WA22762 visit (Week 97) of inflammatory joint disease other than rheumatoid arthritis
• Uncontrolled disease states, such as asthma or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
• Evidence of serious uncontrolled concomitant disease
• Known active current or history of recurrent infection
• Primary or secondary immunodeficiency (history of or currently active)
• Body weight > 150 kg
• Pregnant or lactating women
• Inadequate hematologic, renal or liver function